OPEN END-TURBO-OPTIONSSCHEIN - ROCHE GS Share Price

Certificat

DE000HG2TAP8

Real-time BOERSE MUENCHEN 01:15:00 03/06/2024 pm IST
1.04 EUR -1.89% Intraday chart for OPEN END-TURBO-OPTIONSSCHEIN - ROCHE GS
1 month-9.40%
3 months-10.17%
Date Price Change
03/24/03 1.04 -1.89%
31/24/31 1.06 -1.85%
30/24/30 1.08 +3.85%
29/24/29 1.04 -0.95%
28/24/28 1.05 +0.96%

Real-time BOERSE MUENCHEN

Last update June 03, 2024 at 01:15 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying ROCHE HOLDING AG
Issuer HSBC
WKN HG2TAP
ISINDE000HG2TAP8
Date issued 03/05/2022
Strike 332.7 CHF
Maturity Unlimited
Parity 100 : 1
Emission price 0.12
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.29
Lowest since issue 0.16
Spread 0.01
Spread %0.96%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus